Karyopharm Therapeutics
KPTI
68 hedge funds and large institutions have $69.6M invested in Karyopharm Therapeutics in 2025 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 19 increasing their positions, 5 reducing their positions, and 10 closing their positions.
280% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 5
258% more capital invested
Capital invested by funds: $19.5M → $69.6M (+$50.1M)
160% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 10
31% more funds holding
Funds holding: 52 → 68 (+16)
21.14% more ownership
Funds ownership: 34.32% → 55.46% (+21%)
1% more call options, than puts
Call options by funds: $4.81M | Put options by funds: $4.75M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$5.69M |
| 2 |
AAA
Affinity Asset Advisors
New York
|
+$5.44M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$4.83M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$3.16M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$2.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Birchview Capital
Burlington,
Vermont
|
-$183K |
| 2 |
Goldman Sachs
New York
|
-$163K |
| 3 |
Morgan Stanley
New York
|
-$103K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$92K |
| 5 |
Belvedere Trading
Chicago,
Illinois
|
-$89.1K |
KPTI Hedge Fund Activity: Q4 2025 in Review
68 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q4 2025, worth a combined $69.6M — up 258% from $19.5M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new KPTI positions and 10 closed out — a net gain of 16 holders — while 19 added to existing stakes and 5 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $5.69M. The largest seller was Birchview Capital, exiting entirely with an estimated $183K sold.
- 68 institutional investors held Karyopharm Therapeutics (KPTI) as of Q4 2025, up from 52 in Q3 2025.
- Funds reported $69.6M of Karyopharm Therapeutics stock for Q4 2025, up 258% quarter-over-quarter.
- 26 funds opened new Karyopharm Therapeutics positions in Q4 2025 and 10 closed out, a net change of +16 holders.
- The largest Karyopharm Therapeutics buyer in Q4 2025 was Opaleye Management, an estimated $5.69M added.
- The largest Karyopharm Therapeutics seller in Q4 2025 was Birchview Capital, an estimated $183K sold.
Based on aggregated 13F filings for Q4 2025.